Molecular network-based identification of competing endogenous RNAs in bladder cancer

Wei-dong Jiang, Ping-cheng Yuan

Department of Urology and Hubei Key Laboratory of Kidney Disease Pathogenesis and Intervention, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Edong Healthcare Group, Huangshi, China

*dryuanpc@sina.com

Abstract

Background

Circular RNAs (circRNAs) have been shown to interact with microRNAs (miRNA) as competitive endogenous RNAs (ceRNAs) to regulate target gene expression and participate in tumorigenesis. However, the role of circRNA-mediated ceRNAs in bladder cancer (BC) remains unknown. Accordingly, the aim of this study was to elucidate the regulatory mechanisms in BC based on construction of the ceRNA network.

Methods

The RNA expression profiles were obtained from public datasets in the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) database, and were used to establish a circRNA-miRNA-mRNA network. The interactions among proteins were analyzed using the STRING database and hubgenes were extracted using the cytoHubba application. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses of differentially expressed mRNAs in BC and normal tissue samples were performed to determine the functions of the intersecting mRNAs.

Results

A total of 27 circRNAs, 76 miRNAs, and 4744 mRNAs were found to be differentially expressed between BC and normal tissues. The circRNA-miRNA-mRNA ceRNA network was established based on 21 circRNAs, 14 miRNAs, and 150 mRNAs differentially expressed in BC. We also established a protein-protein interaction network and identified 10 hubgenes, which were used to construct circRNA-miRNA-hubgene regulatory modules. The most enriched biological process GO term was strand displacement (P<0.05), and the homologous recombination and Fanconi anemia pathways were significantly enriched (P<0.05) for the differentially expressed genes in BC.

Conclusions

We screened several dysregulated circRNAs and established a circRNA-associated ceRNA network by bioinformatics analysis. The identified ceRNAs are likely critical in the pathogenesis of BC and may serve as future therapeutic biomarkers.
Introduction

Bladder cancer (BC) is one of the most commonly diagnosed genitourinary malignancies representing a major threat to public health [1]. Although the current clinical treatment of BC has progressed vastly, the 5-year overall survival (OS) remains unsatisfying, especially for patients with metastatic BC [1, 2]. Furthermore, BC has a high recurrence rate (50%), and 15-40% of cases develop into a muscle-invasive form of the disease [3, 4]. Therefore, it is of great importance to clarify the potential molecular mechanisms that may trigger BC, as well as to identify novel targets for disease treatment, which could in turn improve the prognosis and outcome for patients.

Circular RNAs (circRNAs) are novel non-coding RNAs, and are highly conserved across species [5]. Their name originates from the fact that they form closed ring structures without 5' caps and 3' tails, conferring them with resistance to exonuclease providing greater stability than linear RNAs [6, 7]. Accumulating evidence indicates that circRNAs could serve as novel prognostic markers in multiple tumor types, such as hepatocellular carcinoma, gastric cancer, and glioblastoma [8–10]. Leonardo Salmena et al. [11] proposed the competitive endogenous RNA (ceRNA) hypothesis in 2011, which posits that a complex post-transcriptional regulatory network of circRNAs can function as a microRNA(miRNA) sponge by complementary base pairing with targeted miRNA using miRNA response elements, thereby inhibiting the activity of miRNAs in regulating the expression of their downstream target genes to contribute to multiple malignancies. Supporting this hypothesis, Wu et al demonstrated that CEP128 acts as a ceRNA to regulate SOX11 expression by sponging miR-145-5p, thereby reducing its inhibitory effect of miR-145-5p on SOX11 in BC [12]. Furthermore, the circRNA hsa_circ_000984 was shown to be significantly upregulated in colorectal cancer (CRC) tissues and cell lines. Knockdown of hsa_circ_000984 inhibited the proliferation, migration, and invasion in vitro and tumor formation in vivo in CRC cell lines. eCDK6 was a downstream mRNA target of miR-106b, its expression was positively regulated by hsa_circ_000984 and negatively regulated by miR-106b. Thus, the authors concluded that hsa_circ_000984 may act as a ceRNA to regulate CDK6 expression in CRC by sponging miR-106b [13].

In our study, we obtained the circRNA, mRNA, and miRNA expression profiles from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) database. The flow chart of ceRNA network analysis is shown in Fig 1. After predicting the sponge miRNA of circRNA and miRNA target genes, we successfully constructed a circRNA-miRNA-mRNA network and circRNA-miRNA-hubgene network for BC. To better understand the underlying mechanisms contributing to the pathogenesis, we conducted protein-protein interaction (PPI) and functional enrichment analyses of the differentially expressed genes (DEGs) in the networks. These results can provide further insight into the roles of circRNAs in carcinogenesis, and highlight new treatment targets or biomarkers for BC. Indeed, some of the differentially expressed RNAs identified have been reported in BC previously, but the majority have not, providing new opportunities for novel research directions in this field [14–16]. Given the poor prognosis and high rate of recurrence for patients with BC, these data can offer new opportunities for improving treatment and prevention.

Materials and methods

Data acquisition and processing

The circRNA expression profile of the GSE92675 dataset was downloaded from the GEO database, including data from four BC tissues and four normal tissues. The mRNA (414 BC tissues and 19 normal tissues) and miRNA (418 BC tissues and 19 normal tissues) expression profiles
were obtained from TCGA database. No ethical approval nor informed consent was required in this study due to the public-available data of GEO. No ethical approval or informed consent was required in this study owing to the use of publicly available data.

**Identification of DEGs**

We applied the Limma package to identify differentially expressed circRNAs (DEcircRNAs) with a threshold of $|\log_2 \text{fold change (FC)}| > 3$ and adjusted $P$-value $< 0.01$. The differentially expressed mRNAs (DEmRNAs) and miRNAs (DEmiRNAs) were analyzed using the edgeR package with thresholds of $|\log_2 \text{FC}| > 1$ and an adjusted $P$-value $< 0.05$. 

Fig 1. The flowchart of ceRNA network analysis.

https://doi.org/10.1371/journal.pone.0220118.g001
**Construction of the ceRNA network**

The circRNA-miRNA interactions were predicted using the Circular RNA Interactome (Circular RNA Interactome) [https://circinteractome.nia.nih.gov/](https://circinteractome.nia.nih.gov/) databases. These target miRNAs were further screened according to the DEmiRNAs obtained from TCGA database. In addition, miRNA-targeted mRNAs were retrieved from the miRTarBase and TargetScan databases [17, 18]. Only mRNAs recognized by both databases were considered to be candidate targets, and were intersected with the identified DEmRNAs to screen out the DEmRNAs targeted by the DEmiRNAs. Based on these DEmiRNA-DEcircRNA and DEmiRNA-DEmRNA interactions, we constructed circRNA-miRNA-mRNA regulatory network, which was visualized using Cytoscape 3.7.0 software.

**PPI network construction and analysis**

The Search Tool for the Retrieval of Interacting Genes database (Version 10.0, [http://string-db.org](http://string-db.org)) was used to predict potential interactions among DEmRNAs. A combined score of > 0.4 was considered significant. Cytoscape 3.7.0 was used for visualization. We used the cytoHubba application to explore the hub genes of the obtained PPI network [19].

**GO annotation and KEGG pathway analysis**

The Gene Ontology (GO) annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed using the clusterProfiler package of R software [20]. P value less than 0.05 were considered to represent statistically significant enrichment of DEGs in pathways or GO terms.

**Results**

**Differentially expressed RNAs**

We found 27 DEcircRNAs from the GSE92675 dataset, including 21 up-regulated and 6 down-regulated circRNAs in BC tissues (Fig 2A). We also obtained 76 DEmiRNAs (19 up-regulated and 57 downregulated) and 4744 DEmRNAs (2776 upregulated and 1968 downregulated mRNAs) from RNA-Seq data between BC tissues and normal bladder tissues (Fig 2B and 2C).

![Fig 2. Volcano plot of differentially expressed circRNAs, miRNAs, and mRNAs.](https://doi.org/10.1371/journal.pone.0220118.g002)
Construction of the ceRNA network

To further examine the underlying mechanism of circRNA in mediating mRNA based on miRNA, a ceRNA network was established. We predicted the miRNAs targeted by the 27 DEcircRNAs using the CircInteractome online database. A total of 660 circRNA-miRNA pairs were identified. After intersecting with the DEmiRNAs, 37 circRNA-miRNA pairs, including 21 circRNAs and 14 DEmiRNAs, remained. We further searched for mRNAs targeted by these 14 DEmiRNAs from the miRTarBase and TargetScan databases, and selected those overlapping with the identified DEmiRNAs. Ultimately, a total of 150 DEmRNAs were involved in the ceRNA network, along with 21 circRNAs, and 14 miRNAs (Fig 3).

Construction of the PPI network

After removing unconnected nodes, we established a PPI network that contained 46 nodes and 53 edges (Fig 4A). To explore the hubgenes in the network, indicating a critical role in the
In the process of BC carcinogenesis, the degree and betweenness centrality were evaluated, and the following top 10 hub genes were extracted using the cytoHubba app: CDK1, CENPM, CENPF, KNTC1, DSN1, HIST1H2BJ, RAD51, EZH2, EXO1, and BRCA1 (Fig 4B). Based on this result, we established a circRNA-miRNA-hub gene subnetwork, including 31 ceRNA regulatory modules. After excluding modules with inconsistent expression of circRNAs and mRNAs, 29 modules remained (Fig 5).

**Functional assessment**

To provide insight into the underlying biological processes and pathways related to the DEmRNAs in the ceRNA network, we performed the GO annotation and KEGG pathway analyses. GO analysis showed that the DEmRNAs were, most significantly enriched in the biological process, cellular components, and molecular function terms strand displacement, condensed chromosome, and endodeoxyribonuclease activity, respectively (P < 0.05). The top five GO terms are indicated in Table 1. In addition, the DEmRNAs were significantly enriched in two KEGG pathways: homologous recombination and Fanconi anemia pathway.

**Discussion**

In recent years, several computational models have been developed to identify cancer-related non-coding RNAs, and some of them perform well, such as Inductive Matrix Completion for MiRNA–Disease Association prediction (IMCMDA), Matrix Decomposition and Heterogeneous Graph Inference (MDHGI), and Laplacian Regularized Sparse Subspace Learning for MiRNA-Disease Association prediction (LRSSLMDA) [21–24]. However, few computational models predict potential associations between circRNAs and bladder cancer. Our study aims to establish a circRNA-miRNA-mRNA regulatory network.

CircRNAs were first identified in viruses in the 1970s, and then subsequently discovered to be present in human cell lines and the human body [25, 26]. Since circRNAs lack 5' or 3' polarities or polyadenylated tails, they are stable and cannot be degraded by RNase-R enzyme [7].
CircRNAs are abundant in eukaryotic cells and show a high degree of conservation, along with structural stability, and a certain degree of organization, timing and disease-specific activity [27, 28]. Based on these features, circRNAs have become research hot spots, especially with respect to cancer research. Recent studies have revealed the abundance and function of circRNAs in tumorigenesis [29, 30] and the mechanisms by which circRNAs participate in regulating malignant biological processes [31, 32], demonstrating their potential to serve as biomarkers of malignancies [33–35]. However, the exact role of circRNAs in BC remains largely unclear. This study represents the first attempt at integrating the differentially expressed circRNAs, miRNAs, and mRNAs in BC from public databases to provide a circRNA-miRNA-mRNA regulatory network.

Indeed, accumulating evidence indicates a role of circRNAs in the initiation and progression of BC [36, 37]. Xu et al. [36] analyzed 40 pairs of BC tissue and blood samples and found that circPTK2 was highly expressed in BC. Moreover, they showed that elevated circPTK2 expression could promote the proliferation and migration of BC cells. Chen et al. [37] found that circPRMT5 expression was elevated in BC tissues and was associated with an advanced
clinical stage and poor OS of BC patients. They further revealed that circPRMT5 promotes the metastasis of urothelial carcinoma of the bladder through sponging miR-30c to induce the epithelial-mesenchymal transition. In our study, we analyzed BC samples and normal renal samples and found 21 circRNAs involved in the ceRNA network based on analysis of BC tissues and normal renal samples, including hsa_circ_0000144 and hsa_circ_0023642, whose dysregulated expression has been associated with the pathogenesis and prognosis of BC, indicating their potential as tumor-related biomarker [38, 39]. However, none of the other 19 circRNAs in our ceRNA network have been reported in BC to date.

MiRNAs are non-coding single-stranded RNA molecules that consist of approximately 22 nucleotides [40]. The aberrant expression of miRNAs, which regulate the expression of multiple oncogenes and tumor suppressors, has been widely associated with cancer development [41]. In this study, we identified 14 DEMiRNAs in the ceRNA network. Some researchers have studied the binding of circRNAs to miRNAs and their interactions in BC [14, 42]. Li et al. [14] demonstrated that the circRNA Cdr1as expression inhibited BC cell proliferation, apoptosis, and invasion by sponging miR-135a. Yang et al. [42] indicated that circ-ITCH inhibits BC progression by sponging miR-17/miR-224 and regulating p21 and PTEN expression. Of the 14 miRNAs involved in our ceRNA network, four have been reported to play important roles in the initiation and development of BC, including miR-217, miR-375, and miR-431, and miR-935 [38, 43–45].

To further identify the key circRNAs participating in the regulatory network, we established the PPI network, and screening out 10 hub genes, followed by construction of the circRNA-miRNA-hubgene network, including 29 ceRNA regulatory modules. To understand the underlying biological processes and pathways between DEMiRNAs in the ceRNA network, we performed the functional enrichment analyses. The result indicated that the DEMiRNAs were significantly enriched in homologous recombination and Fanconi anemia pathway. Qiao et al. [46] indicated that Imatinib can radiosensitize BC by targeting homologous recombination. In addition, Madubata et al. [47] found that BC patients with Fanconi anemia nonsense variants display a BRCA-deficiency somatic mutation signature. Therefore, the DEMiRNAs are involved in many important BC-associated biological functions and metabolic pathways.
However, our study presents several limitations. First, the number of samples is not very large. In the future, we will do more analysis based on large samples. Second, the conclusions of our study are only based on the current existing tools and databases. These conclusions are further validated by real experiments. In addition, deep learning, such as graph convolutional neural networks (GCN), convolutional neural networks (CNN), has invaded the field of bioinformatics [48, 49]. In the future, we will try some analysis based on deep learning. Third, the prognostic value of these DEcircRNAs in BC has not been evaluated. In future studies, we will collect more clinical samples validate our findings and further explore the function of these DEcircRNAs using in vitro and in vivo experiments.

Conclusions
In this study, we constructed the first ceRNA network in bladder cancer, by identifying DEmiRNAs, DEmRNAs, and DEcircRNAs between BC and normal tissues from data in public databases. Based on these interactions, we identified miRNA and circRNA targets and constructed a protein interaction network to highlight hub genes with likely involvement in BC pathogenesis. We further conducted functional analyses of the DEGs to provide insight into the key biological processes involved in this regulation network. We believe that our study makes a significant contribution to the literature because the roles of circRNAs as potential miRNA "sponges" in several types of cancers are increasingly being emphasized, including BC. Our constructed networks and corresponding modules can serve as a useful guide for further targeted research into the molecular pathogenesis of BC to identify new therapeutic targets and/or biomarkers.

Supporting information
S1 Table. circRNA expression matrix.

(TXT)

Author Contributions
Conceptualization: Wei-dong Jiang, Ping-cheng Yuan.
Data curation: Wei-dong Jiang, Ping-cheng Yuan.
Formal analysis: Wei-dong Jiang, Ping-cheng Yuan.
Investigation: Wei-dong Jiang, Ping-cheng Yuan.
Methodology: Wei-dong Jiang, Ping-cheng Yuan.
Project administration: Wei-dong Jiang, Ping-cheng Yuan.
Resources: Wei-dong Jiang, Ping-cheng Yuan.
Software: Wei-dong Jiang, Ping-cheng Yuan.
Supervision: Wei-dong Jiang, Ping-cheng Yuan.
Validation: Wei-dong Jiang, Ping-cheng Yuan.
Visualization: Wei-dong Jiang, Ping-cheng Yuan.
Writing – original draft: Wei-dong Jiang, Ping-cheng Yuan.
Writing – review & editing: Wei-dong Jiang, Ping-cheng Yuan.
References

1. Babjuk M, Burger M, Comperat E, Palou J, Roupert M, van Rhijn B, et al. Reply to Harry Herr’s Letter to the Editor re: Marko Babjuk, Andreas Bohle, Maximilian Burger, et al. EAU Guidelines on Non-muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol 2017; 71:447–61. European urology. 2017;71(6):e173-e4. Epub 2016/12/13. https://doi.org/10.1016/j.eururo.2016.05.041 PMID: 27324428.

2. Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, et al. NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. J Natl Compr Canc Netw. 2016; 14(10):1213–24. Epub 2016/10/05. PMID: 2769776; PubMed Central PMCID: PMC5379654.

3. Amin MB, Smith SC, Reuter VE, Epstein JI, Grignon DJ, Hanse l DE, et al. Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer. Mod Pathol. 2015; 28(5):612–30. Epub 2014/11/22. https://doi.org/10.1038/modpathol.2014.158 PMID: 25412849; PubMed Central PMCID: PMC5099623.

4. Kang M, Jeong CW, Kwak C, Kim HH, Ku JH. Preoperative neutrophil-lymphocyte ratio can significantly predict mortality outcomes in patients with non-muscle invasive bladder cancer undergoing transure- thral resection of bladder cancer. Oncotarget. 2017; 8(8):12891–901. Epub 2017/01/01. https://doi.org/10.18632/oncotarget.14179 PMID: 28039452; PubMed Central PMCID: PMC5355064.

5. Chen LL. The biogenesis and emerging roles of circular RNAs. Nat Rev Mol Cell Biol. 2016; 17(4):205–11. Epub 2016/02/26. https://doi.org/10.1038/nrm.2015.32 PMID: 26908011.

6. Liu J, Liu T, Wang X, He A. Circles reshaping the RNA world: from waste to treasure. Mol Cancer. 2017; 16(1):58. Epub 2017/03/11. https://doi.org/10.1186/s12943-017-0630-y PMID: 28279183; PubMed Central PMCID: PMC5345220.

7. Li J, Yang J, Zhou P, Le Y, Zhou C, Wang S, et al. Circular RNAs in cancer: novel insights into origins, properties, functions and implications. Am J Cancer Res. 2015; 5(2):472–80. Epub 2015/05/15. PMID: 25973291; PubMed Central PMCID: PMC4396047.

8. Liu M, Liu KD, Cai J, Yao HW, Bai YK, et al. CircRNA_Cdr1as Exerts Anti-Oncog enic Func-

9. Zhuang C, Huang X, Yu J, Gui Y. Circular RNA has_circ_0075828 promotes bladder cancer cell prolif-

10. Zhang J, Chang Y, Xu L, Qin L. Elevated expression of circular RNA circ_0008450 predicts dismal prog-

11. Epub 2015/10/05. PMID: 2769776; PubMed Central PMCID: PMC5379654.

12. Fromm B, Billipp T, Peck LE, Johansen M, Tarver JE, King BL, et al. A Uniform System for the Annotation of Vertebrate microRNA Genes and the Evolution of the Human microRNAome. Annu Rev Genet. 2015; 49:213–42. Epub 2015/10/17. https://doi.org/10.1146/annurev-genet-120213-092023 PMID: 26473382; PubMed Central PMCID: PMC4743252.
19. Bandettini WP, Killman P, Mancini C, Booker OJ, Vasu S, Leung SW, et al. MultiContrast Delayed Enhancement (MCODE) improves detection of subendocardial myocardial infarction by late gadolinium enhancement cardiovascular magnetic resonance: a clinical validation study. J Cardiovasc Magn Reson. 2012; 14(83). Epub 2012/12/04. https://doi.org/10.1186/1532-429X-14-83 PMID: 23199362; PubMed Central PMCID: PMC3552709.

20. Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284–7. Epub 2012/03/30. https://doi.org/10.1089/omi.2011.0118 PMID: 22455463; PubMed Central PMCID: PMC3339379.

21. Chen X, Yin J, Qu J, Huang L. MDHG1: Matrix Decomposition and Heterogeneous Graph Inference for miRNA-disease association prediction. PLoS Comput Biol. 2018; 14(8):e1006418. https://doi.org/10.1371/journal.pcbi.1006418 PMID: 30142158; PubMed Central PMCID: PMC6126877.

22. Chen X, Huang L. LRSSLMDA: Laplacian Regularized Sparse Subspace Learning for MiRNA-Disease Association Prediction. PLoS Comput Biol. 2017; 13(12):e1005912. https://doi.org/10.1371/journal.pcbi.1005912 PMID: 29235895; PubMed Central PMCID: PMC5749861.

23. Chen X, Xie D, Zhao Q, You Z-H. MicroRNAs and complex diseases: from experimental results to computational models. Briefings in Bioinformatics. 2019; 20(2):515–39. https://doi.org/10.1093/bib/bbx130 PMID: 29045695.

24. Chen X, Wang L, Qu J, Guan NN, Li JQ. Predicting miRNA-disease association based on inductive matrix completion. Bioinformatics. 2018; 34(24):4256–65. https://doi.org/10.1093/bioinformatics/bty503 PMID: 29939227.

25. Sanger HL, Klotz G, Riesner D, Gross HJ, Kleinschmidt AK. Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures. Proc Natl Acad Sci U S A. 1976; 73(11):3852–6. Epub 1976/11/01. https://doi.org/10.1073/pnas.73.11.3852 PMID: 1069269; PubMed Central PMCID: PMC431239.

26. Cocquerelle C, Mascrèz B, Hetuin D, Bailleul B. Mis-splicng yields circular RNA molecules. FASEB J. 1993; 7(1):155–60. Epub 1993/01/01. https://doi.org/10.1096/fasebj.7.1.767559 PMID: 7675599.

27. Jeck WR, Sorrentino JA, Wang K, Slevin MK, Burd CE, Liu J, et al. Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA. 2013; 19(2):141–57. Epub 2012/12/20. https://doi.org/10.1261/rna.035667.112 PMID: 23249747; PubMed Central PMCID: PMC3543092.

28. Rybak-Wolf A, Stöttmeister C, Glazar P, Jens M, Pino N, Giusti S, et al. Circular RNAs in the Mammalian Brain Are Highly Abundant, Conserved, and Dynamically Expressed. Mol Cell. 2015; 58(5):870–85. Epub 2015/04/30. https://doi.org/10.1016/j.molcel.2015.03.027 PMID: 29939227.

29. Kristensen LS, Hansen TB, Veno MT, Kjems J. Circular RNAs in cancer: opportunities and challenges in the field. Oncogene. 2018; 37(5):555–65. Epub 2017/10/11. https://doi.org/10.1038/onc.2017.361 PMID: 28999123; PubMed Central PMCID: PMC5799710.

30. Zhong Y, Du Y, Yang X, Mo Y, Fan C, Xiong F, et al. Circular RNAs function as ceRNAs to regulate and control human cancer progression. Mol Cancer. 2018; 17(1):79. Epub 2018/04/09. https://doi.org/10.1186/s12953-018-0827-6 PMID: 29626935; PubMed Central PMCID: PMC5799710.

31. Zhou B, Zheng P, Li Z. CircPCNXL2 sponges miR-153 to promote the proliferation and invasion of renal cancer cells through upregulating ZEB2. Journal of translational medicine. 2018; 17(23):2644–54. Epub 2018/12/19. https://doi.org/10.1186/s12967-018-1726-x PMID: 30488672.

32. Lv C, Sun L, Guo Z, Li H, Kong D, Xu B, et al. Circular RNA regulatory network reveals cell-cell crosstalk in acute myeloid leukemia extramedullary infiltration. Journal of translational medicine. 2018; 16(1):361. https://doi.org/10.1186/s12967-018-1726-x PMID: 29626935; PubMed Central PMCID: PMC5799710.

33. Jin Y, Yu LL, Zhang B, Liu CF, Chen Y. Circular RNA has_circ_0000523 regulates the proliferation and apoptosis of colorectal cancer cells as miRNA sponge. Braz J Med Biol Res. 2018; 51(12):e7811. Epub 2018/11/08. https://doi.org/10.1590/1414-431X20187811 PMID: 30403259; PubMed Central PMCID: PMC56233523.

34. Zhang X, Xu Y, Oian Z, Zheng W, Wu Q, Chen Y, et al. circRNA_104075 stimulates YAP-dependent tumorigenesis through the regulation of HNF4a and may serve as a diagnostic marker in hepatocellular carcinoma. Cell Death Dis. 2018; 9(11):1091. Epub 2018/10/27. https://doi.org/10.1038/s41419-018-1132-6 PMID: 30361504; PubMed Central PMCID: PMC6202383.

35. Yu H, Chen Y, Jiang P. Circular RNA HIPK3 exerts oncogenic properties through suppression of miR-124 in lung cancer. Biochem Biophys Res Commun. 2018; 506(3):455–62. Epub 2018/10/26. https://doi.org/10.1016/j.bbrc.2018.10.087 PMID: 30352682.

36. Xu ZQ, Yang MG, Liu HJ, Su CQ. Circular RNA has_circ_0003221 (circPTK2) promotes the proliferation and migration of bladder cancer cells. J Cell Biochem. 2018; 119(4):3317–25. Epub 2017/11/11. https://doi.org/10.1002/jcb.26492 PMID: 29125888.

37. Chen X, Chen RX, Wei WS, Li YH, Feng ZH, Tan L, et al. PRMT5 Circular RNA Promotes Metastasis of Urothelial Carcinoma of the Bladder by Spouncing miR-30c to Induce Epithelial-Mesenchymal Transitions.
38. Huang W, Lu Y, Wang F, Huang X, Yu Z. Downregulation of circular RNA hsa_circ_0000144 inhibits bladder cancer progression via stimulating miR-217 and suppressing RUNX2 expression. Gene. 2018; 678:337–42. Epub 2018/08/12. https://doi.org/10.1016/j.gene.2018.08.036 PMID: 30098434.

39. Yang C, Wu S, Wu X, Zhou X, Jin S, Jiang H. Silencing circular RNA UVRAG inhibits bladder cancer growth and metastasis by targeting the microRNA-223/fibroblast growth factor receptor 2 axis. 2019; 110(1):99–106. https://doi.org/10.10111/cas.13857 PMID: 30387298.

40. Bartel DP. Metazoan MicroRNAs. Cell. 2018; 173(1):20–51. Epub 2018/03/24. https://doi.org/10.1016/j.cell.2018.03.006 PMID: 29570994; PubMed Central PMCID: PMC6091663.

41. Liu C, Liu R, Zhang D, Deng Q, Liu B, Chao HP, et al. MicroRNA-141 suppresses prostate cancer stem cells and metastasis by targeting a cohort of pro-metastasis genes. Nat Commun. 2017; 8:14270. Epub 2017/01/24. https://doi.org/10.1038/ncomms14270 PMID: 28112170; PubMed Central PMCID: PMC5264244.

42. Yang C, Yuan W, Yang X, Li P, Wang J, Han J, et al. Circular RNA circ-ITCH inhibits bladder cancer progression by sponging miR-17/miR-224 and regulating p21, PTEN expression. Mol Cancer. 2018; 17 (1):19. Epub 2018/04/26. https://doi.org/10.1186/s12943-018-0771-7 PMID: 29386015; PubMed Central PMCID: PMC5793418.

43. Du L, Jiang X, Duan W, Wang R, Wang L, Zheng G, et al. Cell-free microRNA expression signatures in urine serve as novel noninvasive biomarkers for diagnosis and recurrence prediction of bladder cancer. Oncotarget. 2017; 8(25):40832–42. Epub 2017/04/06. https://doi.org/10.18632/oncotarget.16586 PMID: 28388561; PubMed Central PMCID: PMC5522322.

44. Li WT, Zheng H, Nguyen V, Wang-Rodriguez J, Ongkeko WM. Functional Genomics Profiling of Bladder Urothelial Carcinoma MicroRNAome as a Potential Biomarker. Neoplasia (New York, NY). 2018; 20 (4):364–73. Epub 2018/03/16. https://doi.org/10.1016/j.neo.2018.01.008 PMID: 29544183; PubMed Central PMCID: PMC5857480.

45. Wei Y, He R, Wu Y, Gan B, Wu P, Qiu X, et al. Comprehensive investigation of aberrant microRNA profiling in bladder cancer tissues. 2016; 37(9):12555–69. https://doi.org/10.1007/s13277-016-5121-z PMID: 27350368.

46. Qiao B, Ken M, Groselj B, Teo MT, Knowles MA, Bristow RG, et al. Imatinib radiosensitizes bladder cancer by targeting homologous recombination. Cancer Res. 2013; 73(5):1611–20. Epub 2013/01/11. https://doi.org/10.1158/0008-5472.CAN-12-1170 PMID: 23302226; PubMed Central PMCID: PMC3590104.

47. Madubata CJ, Roshan-Ghias A, Chu T, Resnick S, Zhao J, Arnes L, et al. Identification of potentially oncogenic alterations from tumor-only samples reveals Fanconi anemia pathway mutations in bladder carcinomas. NPJ genomic medicine. 2017; 2:29. Epub 2017/12/22. https://doi.org/10.1038/s41525-017-0032-5 PMID: 29263839; PubMed Central PMCID: PMC5677944.

48. Li Y, Huang C, Ding L, Li Z, Pan Y, Gao X. Deep learning in bioinformatics: Introduction, application, and perspective in the big data era. Methods. 2019. Epub 2019/04/26. https://doi.org/10.1016/j.ymeth.2019.04.008 PMID: 31022451.

49. Pla A, Zhong X, Rayner S. miRAW: A deep learning-based approach to predict microRNA targets by analyzing whole microRNA transcripts. 2018; 14(7):e1006185. https://doi.org/10.1371/journal.pcbi.1006185 PMID: 30005074.